YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
UCB SA (UCBJY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock pric…
On Monday, President Trump announced that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies to lower drug prices in the country. These companies include Alcon, Astellas Pharma ALPMY…
[Inspecting capsules before production] Dejan Sarec/iStock via Getty Images U.S. President Donald Trump introduced a new set of drug-pricing deals with global pharmaceutical companies and smaller biotechs on Monday, advancing efforts to cu…
(Bloomberg) -- The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd. Most Read from Bloomberg Nvidia to…
This article first appeared on GuruFocus. Total Net Sales: Grew 23% to EUR4.1 billion in H1 2026. Total Revenue: Increased 22% (27% at constant rate) to EUR4.3 billion. Adjusted Gross Profit: Reached EUR3.5 billion, up 27% (33% at constant…
Investing.com - European shares traded in a narrow range on Thursday, as a massive wave of solid corporate earnings led by an energetic profit beat from oil major Shell helped offset an ambiguous interest rate outlook from the Federal Rese…
Biogen Inc. Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses th…
Biogen Inc.; UCB Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus plac…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Investors may be wondering if UCB's share price still reflects good value after a strong run, or…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Conference data puts UCB’s neurology pipeline in focus UCB (ENXTBR:UCB) is in the spotlight after presenting 21 neurology ab…
Belgian pharma company UCB (UCBJY [https://seekingalpha.com/symbol/UCBJY]) on Friday announced an agreement to acquire Neurona Therapeutics, a U.S.-based developer of cell therapies for neuronal diseases, for a total consideration of up to…
Investors might want to bet on UCB SA (UCBJY), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting sto…
Company Logo UCB S.A. has key market opportunities in developing biopharmaceuticals addressing autoimmune and neurological diseases. Their focus on digital transformation, innovation, and tech partnerships aims to advance product launches…
(RTTNews) - UCB S.A. (UCBJY) announced on Friday that it has presented new post hoc data regarding Bimzelx (bimekizumab) at the American Academy of Dermatology Annual Meeting 2026 held in Denver, which indicates sustained symptom control i…
UCB CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the general meeting of the shareholders (the “General Meeting”) which will be held on Thursday, 30 April 2026, at 11:00 am CEST,…
This article first appeared on GuruFocus. Net Sales Growth: +35% at constant trend. Revenue from Growth Drivers: EUR3.3 billion, more than double from last year. Bimekizumab Revenue: Over EUR2.2 billion in 2025. Adjusted Gross Profit: EUR6…
(RTTNews) - UCB announced an additional upgrade to its 2025 financial guidance. Revenue is expected to exceed 7.6 billion euros, up 24% year-on-year. Excluding non-recurring impact, 2025 adjusted EBITDA margin is anticipated to be higher t…
UCB (ENXTBR:UCB) shares have caught more attention lately thanks to a mix of solid recent performance and strong momentum over the past month. Investors are watching closely to see if this trend continues. See our latest analysis for UCB.…
[Sign for Wall Street in New York City] Pharrel Wiliams MoonLake Immunotherapeutics (NASDAQ:MLTX [https://seekingalpha.com/symbol/MLTX]) traded higher on Tuesday even as Wall Street opted to downgrade the Swiss biotech following a late-sta…
(Bloomberg) -- Shares in Belgium’s UCB SA soared to a record, while rival MoonLake Immunotherapeutics is set to lose most of its value, after the latter announced late-stage trial data for an experimental skin disease drug that analysts sa…
🔎 Microsoft (MSFT): President Trump on Friday called for Microsoft to fire its head of global affairs, who previously worked for the Biden administration. His demand came a day after the company disabled the Israeli Defense Ministry’s acc…
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than…
(RTTNews) - UCB SA (UCBJY), Wednesday announced has released three-year results from its BE HEARD trials demonstrating that BIMZELX or bimekizumab-bkzx, the first and only approved therapy targeting both IL-17A and IL-17F, provided sustain…
Company Logo The Europe refractory epilepsy treatment market is anticipated to grow from $1.34 billion in 2024 to $2.82 billion by 2035, with a CAGR of 6.98% from 2025 to 2035. This shift towards personalized treatment leverages advancemen…
Survey insights reveal that despite many participants living with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS), feelin…
26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies Data include an open-label extension study describing the long-term safety of FINTEPLA®…
UCB SA (UCBJY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting sto…
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than…
Building on the success of its inaugural event, the 2025 UCB HS Summit focused on amplifying the patient voice and tackling critical unmet needs in the HS community. The event brought together over 100 people from across the HS community o…
* UCB SA press release [https://www.ucb.com/investors/magazine/detail/article/stronger-every-semester-from-differentiated-innovation-to-outstanding-delivery] (OTCPK:UCBJF [https://seekingalpha.com/symbol/UCBJF]): 1H revenues increased to €…
Company Logo The epilepsy therapeutics market is growing steadily, driven by rising global epilepsy prevalence and innovative personalized medicine approaches. Despite challenges like drug-resistant epilepsy and high costs, advancements in…
UCB SA (UCBJY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rati…
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy. O…
Inspired by feedback from the hidradenitis suppurativa (HS) community, the campaign aims to raise awareness of BIMZELX and features a broad range of educational materials encouraging patients to discuss treatment options with their healthc…
Phase 3 study met primary and most key secondary clinical endpointsThis marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase 3 resultsResults underscore the impact of UCB’s cont…
Phase 3 study met primary and most key secondary clinical endpoints This marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase 3 results Results underscore the impact of UCB's co…